You are here
- Home
- Table of contents
- Table of contents
Table of contents
April 2017 - Volume 2 - 1
A
Ansaloni, Silvia
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Aprile, Giuseppe
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Arnoldi, Ermenegildo
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Aschele, Carlo
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Azambuja, Evandro de
- Male breast cancer: finding the way in this uncommon pathChristian Maurer, Samuel Martel, Evandro de AzambujaESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169
B
Baba, Hideo
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Banerjee, Susana
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Barrueco, José
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Beretta, Giordano D
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Bhattacharjee, Atanu
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Boku, Narikazu
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
C
Caglevic, Christian
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
Carnaghi, Carlo
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Cervantes, Andrés
- In the literature: February 2017Andrés Cervantes, María José TerolESMO Open Mar 2017, 2 (1) e000171; DOI: 10.1136/esmoopen-2017-000171
Chan, Anthony TC
- Biologics and biosimilars: what, why and how?Juliana CN Chan, Anthony TC ChanESMO Open Mar 2017, 2 (1) e000180; DOI: 10.1136/esmoopen-2017-000180
Chan, Juliana CN
- Biologics and biosimilars: what, why and how?Juliana CN Chan, Anthony TC ChanESMO Open Mar 2017, 2 (1) e000180; DOI: 10.1136/esmoopen-2017-000180
Chandrasekharan, Arun
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Cheng, Ann-Lii
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Chouaki, Nadia
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Choughule, Anuradha Bharat
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Cosimelli, Maurizio
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
D
Degli Esposti, Claudia
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Della-Pepa, Chiara
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Dolly, Saoirse O
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
E
Egawa, Shinichi
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
F
Ferri, Jose
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
Funakoshi, Akihiro
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Furuse, Junji
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
G
Gann, Claudia-Nanette
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Garrido, Pilar
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Gaschler-Markefski, Birgit
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Giraud, Philippe
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Goel, Alok
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Gottfried, Maya
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Goud, Supriya
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
H
Hagiwara, Yasuhiro
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Hanna, Nasser H
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Hashida, Hiroki
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Hashimoto, Kazuki
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Hatachi, Yukimasa
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Hatori, Takashi
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Hattori, Takayuki
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Hayashi, Hidetoshi
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Hazell, Steve
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Heymach, John V
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Hohokabe, Eri
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
I
Ichikawa, Chihiro
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Imagumbai, Toshiyuki
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Imai, Yukihiro
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Ioka, Tatsuya
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Iwamoto, Shigeyoshi
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
J
Janu, Amit
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Joshi, Amit
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
K
Kaihara, Satoshi
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kaiser, Rolf
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Karpe, Ashay
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Kato, Hironori
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Kato, Ryoji
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Kato, Takeshi
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kaye, Stanley B
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Khakoo, Shelize
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Kihara, Kiyohiro
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Kikawa, Yuichiro
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Kobayashi, Hiroyuki
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kokubo, Masaki
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Komatsu, Yoshito
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Kondo, Masato
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kosaka, Yasuhiro
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Kotaka, Masahito
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kotake, Takeshi
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Kumar, Rajiv
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
L
Lelli, Giorgio
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
M
Mahajan, Abhishek
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Maiello, Evaristo
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Martel, Samuel
- Male breast cancer: finding the way in this uncommon pathChristian Maurer, Samuel Martel, Evandro de AzambujaESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169
Martoni, Andrea A
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Matsumoto, Hiroshi
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Maurer, Christian
- Male breast cancer: finding the way in this uncommon pathChristian Maurer, Samuel Martel, Evandro de AzambujaESMO Open Mar 2017, 2 (1) e000169; DOI: 10.1136/esmoopen-2017-000169
Mellemgaard, Anders
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Melotti, Barbara
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Migali, Cristina
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
Miki, Akira
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Mishima, Hideyuki
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Mizumoto, Kazuhiro
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
More, Sucheta
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Morita, Satoshi
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Muro, Kei
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Murotani, Kenta
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Mutri, Vita
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
N
Nakagawa, Kazuhiko
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Nakamura, Masato
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Narukami, Ryo
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Normanno, Nicola
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Noronha, Vanita
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Novello, Silvia
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
O
Ogura, Kengo
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Ohashi, Yasuo
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Ohkawa, Shinichi
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Okita, Yoshihiro
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Okusaka, Takuji
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
P
Pande, Nikhil
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Pannuti, Franco
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Passiglia, Francesco
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
Patil, Vijay Maruti
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Piva, Erico
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Prabhash, Kumar
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Purandare, Nilendu
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
R
Raez, Luis
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
Ramaswamy, Anant
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Reck, Martin
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Ricardi, Umberto
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Rolfo, Christian
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
S
Sakata, Yuh
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Salvatore, Lisa
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Sasaki, Yasutsuna
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Satake, Hironaga
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Sato, Atsushi
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Satoh, Taroh
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Sciallero, Stefania
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Serke, Monika
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Shimada, Ken
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Shimada, Yasuhiro
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Sikken, Patricia
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancerBirgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf KaiserESMO Open Apr 2017, 2 (1) e000102; DOI: 10.1136/esmoopen-2016-000102
Sobrero, Alberto
- The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentationAlberto SobreroESMO Open Mar 2017, 2 (1) e000157; DOI: 10.1136/esmoopen-2017-000157
Soldatenkova, Victoria
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Strocchi, Elena
- Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO studyAndrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco PannutiESMO Open Mar 2017, 2 (1) e000116; DOI: 10.1136/esmoopen-2016-000116
Sugihara, Kenichi
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
T
Takahari, Daisuke
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Takahashi, Keiichi
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Takebe, Sayaka
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Takeda, Masayuki
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Talreja, Vikas
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar PrabhashESMO Open Apr 2017, 2 (1) e000168; DOI: 10.1136/esmoopen-2017-000168
Tanaka, Kaoru
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Tanaka, Masao
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Tanizaki, Junko
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumabRyoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko NakagawaESMO Open Mar 2017, 2 (1) e000145; DOI: 10.1136/esmoopen-2016-000145
Terol, María José
- In the literature: February 2017Andrés Cervantes, María José TerolESMO Open Mar 2017, 2 (1) e000171; DOI: 10.1136/esmoopen-2017-000171
Thungappa, Satheesh
- Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian RolfoESMO Open Mar 2017, 2 (1) e000162; DOI: 10.1136/esmoopen-2017-000162
Tsuji, Akihito
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Tunariu, Nina
- Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategySaoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana BanerjeeESMO Open Apr 2017, 2 (1) e000101; DOI: 10.1136/esmoopen-2016-000101
U
Ueki, Kazuhiro
- Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre surveyYuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki KokuboESMO Open Apr 2017, 2 (1) e000161; DOI: 10.1136/esmoopen-2017-000161
Ueno, Hideki
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
V
Vallejo, Carmen
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
Valvo, Francesca
- Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D BerettaESMO Open Apr 2017, 2 (1) e000147; DOI: 10.1136/esmoopen-2016-000147
Visseren-Grul, Carla
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroupPilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia NovelloESMO Open Mar 2017, 2 (1) e000141; DOI: 10.1136/esmoopen-2016-000141
W
Watanabe, Masahiko
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Y
Yamada, Yasuhide
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Yamaguchi, Taketo
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Yamao, Kenji
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyYasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao TanakaESMO Open Mar 2017, 2 (1) e000151; DOI: 10.1136/esmoopen-2016-000151
Yasui, Hisateru
- Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito TsujiESMO Open Mar 2017, 2 (1) e000130; DOI: 10.1136/esmoopen-2016-000130
Yoshida, Kazuhiro
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135
Yoshida, Motoki
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi SugiharaESMO Open Mar 2017, 2 (1) e000135; DOI: 10.1136/esmoopen-2016-000135